|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DRAM1 |
Gene summary for DRAM1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DRAM1 | Gene ID | 55332 |
| Gene name | DNA damage regulated autophagy modulator 1 | |
| Gene Alias | DRAM | |
| Cytomap | 12q23.2 | |
| Gene Type | protein-coding | GO ID | GO:0006914 | UniProtAcc | A0A024RBF9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55332 | DRAM1 | AEH-subject1 | Human | Endometrium | AEH | 5.93e-08 | 2.75e-01 | -0.3059 |
| 55332 | DRAM1 | GSM5276937 | Human | Endometrium | EEC | 3.30e-03 | 2.17e-01 | -0.0897 |
| 55332 | DRAM1 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 2.21e-04 | 7.16e-02 | -0.1875 |
| 55332 | DRAM1 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.72e-02 | 3.86e-02 | -0.1883 |
| 55332 | DRAM1 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 7.08e-03 | -6.58e-02 | -0.1917 |
| 55332 | DRAM1 | LZE4T | Human | Esophagus | ESCC | 1.19e-03 | 5.19e-02 | 0.0811 |
| 55332 | DRAM1 | LZE24T | Human | Esophagus | ESCC | 1.27e-02 | 8.46e-02 | 0.0596 |
| 55332 | DRAM1 | P2T-E | Human | Esophagus | ESCC | 2.72e-52 | 1.20e+00 | 0.1177 |
| 55332 | DRAM1 | P4T-E | Human | Esophagus | ESCC | 1.81e-12 | 4.08e-01 | 0.1323 |
| 55332 | DRAM1 | P8T-E | Human | Esophagus | ESCC | 6.26e-16 | 3.06e-01 | 0.0889 |
| 55332 | DRAM1 | P9T-E | Human | Esophagus | ESCC | 4.68e-03 | 1.34e-01 | 0.1131 |
| 55332 | DRAM1 | P10T-E | Human | Esophagus | ESCC | 3.50e-07 | 3.93e-02 | 0.116 |
| 55332 | DRAM1 | P11T-E | Human | Esophagus | ESCC | 2.78e-21 | 1.28e+00 | 0.1426 |
| 55332 | DRAM1 | P12T-E | Human | Esophagus | ESCC | 9.96e-11 | 1.61e-01 | 0.1122 |
| 55332 | DRAM1 | P15T-E | Human | Esophagus | ESCC | 2.41e-03 | 1.41e-01 | 0.1149 |
| 55332 | DRAM1 | P16T-E | Human | Esophagus | ESCC | 1.50e-05 | 6.50e-02 | 0.1153 |
| 55332 | DRAM1 | P17T-E | Human | Esophagus | ESCC | 9.11e-05 | 2.73e-01 | 0.1278 |
| 55332 | DRAM1 | P19T-E | Human | Esophagus | ESCC | 1.92e-05 | 6.21e-01 | 0.1662 |
| 55332 | DRAM1 | P20T-E | Human | Esophagus | ESCC | 3.97e-06 | 1.32e-01 | 0.1124 |
| 55332 | DRAM1 | P21T-E | Human | Esophagus | ESCC | 7.77e-22 | 5.11e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00105068 | Endometrium | AEH | regulation of autophagy | 54/2100 | 317/18723 | 1.15e-03 | 9.97e-03 | 54 |
| GO:001050613 | Endometrium | EEC | regulation of autophagy | 55/2168 | 317/18723 | 1.40e-03 | 1.14e-02 | 55 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:001050621 | Liver | HCC | regulation of autophagy | 210/7958 | 317/18723 | 7.59e-18 | 8.45e-16 | 210 |
| GO:00105066 | Lung | IAC | regulation of autophagy | 65/2061 | 317/18723 | 4.97e-07 | 3.14e-05 | 65 |
| GO:001050612 | Lung | AIS | regulation of autophagy | 55/1849 | 317/18723 | 2.46e-05 | 8.04e-04 | 55 |
| GO:001050610 | Oral cavity | OSCC | regulation of autophagy | 198/7305 | 317/18723 | 1.63e-17 | 1.51e-15 | 198 |
| GO:001050615 | Oral cavity | LP | regulation of autophagy | 132/4623 | 317/18723 | 1.82e-11 | 1.28e-09 | 132 |
| GO:001050631 | Oral cavity | NEOLP | regulation of autophagy | 60/2005 | 317/18723 | 8.06e-06 | 1.57e-04 | 60 |
| GO:0010506110 | Thyroid | PTC | regulation of autophagy | 172/5968 | 317/18723 | 8.76e-17 | 7.57e-15 | 172 |
| GO:001050632 | Thyroid | ATC | regulation of autophagy | 180/6293 | 317/18723 | 1.34e-17 | 1.46e-15 | 180 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DRAM1 | SNV | Missense_Mutation | c.410C>G | p.Thr137Arg | p.T137R | Q8N682 | protein_coding | deleterious(0.01) | possibly_damaging(0.703) | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| DRAM1 | SNV | Missense_Mutation | novel | c.626N>T | p.Ala209Val | p.A209V | Q8N682 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| DRAM1 | SNV | Missense_Mutation | novel | c.364N>A | p.His122Asn | p.H122N | Q8N682 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DRAM1 | SNV | Missense_Mutation | c.266N>T | p.Thr89Ile | p.T89I | Q8N682 | protein_coding | tolerated(0.21) | benign(0.27) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DRAM1 | insertion | In_Frame_Ins | novel | c.156_157insTCT | p.Ser53dup | p.S53dup | Q8N682 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DRAM1 | insertion | Nonsense_Mutation | novel | c.157_158insATAGAAAATAGAACATGTTGGCCAGACATG | p.Ser53delinsAsnArgLysTerAsnMetLeuAlaArgHisGly | p.S53delinsNRK*NMLARHG | Q8N682 | protein_coding | TCGA-A7-A0CG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DRAM1 | SNV | Missense_Mutation | novel | c.489N>G | p.Ile163Met | p.I163M | Q8N682 | protein_coding | deleterious(0) | possibly_damaging(0.55) | TCGA-MY-A5BF-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| DRAM1 | deletion | In_Frame_Del | novel | c.109_120delAACCCCTTCCTC | p.Asn37_Leu40del | p.N37_L40del | Q8N682 | protein_coding | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | ||
| DRAM1 | SNV | Missense_Mutation | novel | c.431N>G | p.Ser144Cys | p.S144C | Q8N682 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AA-3872-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| DRAM1 | SNV | Missense_Mutation | novel | c.500N>T | p.Ser167Phe | p.S167F | Q8N682 | protein_coding | deleterious(0.01) | possibly_damaging(0.657) | TCGA-AA-3872-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 55332 | DRAM1 | NA | CISPLATIN | CISPLATIN | 15940259 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |